More specifically, nuclear P-AKT, ERK1/2 and SHARP-2 immunoreactivity within metastatic cancer tissues was lower than that observed within normal breast tissues (p < 0.05, p < 0.05 and p < 0.01, respectively) (Figures 4C, D and 5A). This evidence concerns the gene AKT1 and metastatic malignant neoplasm.